Published in Cancer Weekly, July 6th, 2004
This large, randomized, controlled multi-national study will employ translational medicine to determine the Fc gamma RIIIa genotypes of patients and identify those who are more likely to respond to treatment.
Chiron initiated the new phase II study based on preliminary data from its ongoing phase II study of Proleukin (subcutaneous 14 MIU thrice...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.